Gender differences in risk factors for coronary heart disease

Maturitas

Volumn 65, Issue 2, 2010, Pages 149-160

  Tan, Yen Y ^a   Gast, Gerrie Cor M ^a   van der Schouw, Yvonne T ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Coronary heart disease; Gender; Risk factors

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

DIABETES MELLITUS; FEMALE; HORMONAL THERAPY; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; ISCHEMIC HEART DISEASE; MALE; MENOPAUSE; OBESITY; ORAL CONTRACEPTION; OVARY POLYCYSTIC DISEASE; PHYSICAL ACTIVITY; PREECLAMPSIA; REVIEW; RISK FACTOR; SEX DIFFERENCE; SMOKING;

AGE FACTORS; CONTRACEPTIVES, ORAL; CORONARY DISEASE; DIABETES COMPLICATIONS; EXERCISE; FEMALE; HUMANS; HYPERLIPIDEMIAS; MALE; MENOPAUSE; OBESITY; POLYCYSTIC OVARY SYNDROME; PRE-ECLAMPSIA; PREGNANCY; RISK FACTORS; SEX FACTORS; SMOKING;

EID: 74649085210     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2009.09.023     Document Type: Review

References (73)

1. The global burden of disease: 2004 update (2009), World Health Organization
2. European cardiovascular disease statistics 2008 (2009), European Heart Network (EHN)
3. Banks A.D. Women and heart disease: missed opportunities. J Midwifery Women's Health 53 (2008) 430-439
4. Eastwood J.A., and Doering L.V. Gender differences in coronary artery disease. J Cardiovas Nurs 20 (2005) 340-351
5. Mosca L., Linfante A.H., Benjamin E.J., et al. National study of physician awareness and adherence to cardiovascular disease prevention guidelines. Circulation 111 (2005) 499-510
6. Pilote L., Dasgupta K., Guru V., et al. A comprehensive view of sex-specific issues related to cardiovascular disease. CMAJ: Can Med Assoc J 176 (2007) S1-S44
7. Ehrmann D.A. Polycystic ovary syndrome. N Engl J Med 352 (2005) 1223-1236
8. Talbott E., Guzick D., Clerici A., et al. Coronary heart disease risk factors in women with polycystic ovary syndrome. Arterioscler Thromb Vasc Biol 15 (1995) 821-826
9. Ehrmann D.A., Liljenquist D.R., Kasza K., et al. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 91 (2006) 48-53
10. Solomon C.G., Hu F.B., Dunaif A., et al. Menstrual cycle irregularity and risk for future cardiovascular disease. J Clin Endocrinol Metab 87 (2002) 2013-2017
11. Shaw L.J., Bairey Merz C.N., Azziz R., et al. Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health-National Heart, Lung, and Blood Institute Sponsored Women's Ischemia Syndrome Evaluation. J Clin Endocrinol Metab 93 (2008) 1276-1284
12. Christian R.C., Dumesic D.A., Behrenbeck T., Oberg A.L., Sheedy P.F., and Fitzpatrick L.A. Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome. J Clin Endocrinol Metab 88 (2003) 2562-2568
13. Talbott E.O., Zborowski J.V., Sutton-Tyrrell K., Hugh-Pemu K.P., and Guzick D.S. Cardiovascular risk in women with polycystic ovary syndrome. Obstet Gynecol Clin N Am 28 (2001) 111-133
14. Pierpoint T., McKeigue P.M., Isaacs A.J., Wild S.H., and Jacobs H.S. Mortality of women with polycystic ovary syndrome at long-term follow-up. J Clin Epidemiol 51 (1998) 581-586
15. Wild S., Pierpoint T., McKeigue P., and Jacobs H. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clin Endocrinol 52 (2000) 595-600
16. Bellamy L., Casas J.P., Hingorani A.D., and Williams D.J. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ 335 (2007) 974
17. Garovic V.D., and Hayman S.R. Hypertension in pregnancy: an emerging risk factor for cardiovascular disease. Nat Clin Pract Neph 3 (2007) 613-622
18. McDonald S.D., Malinowski A., Zhou Q., Yusuf S., and Devereaux P.J. Cardiovascular sequelae of preeclampsia/eclampsia: a systematic review and meta-analyses. Am Heart J 156 (2008) 918-930
19. Lampinen K.H., Ronnback M., Kaaja R.J., and Groop P.H. Impaired vascular dilatation in women with a history of pre-eclampsia. J Hyperten 24 (2006) 751
20. Atsma F., Bartelink M.L.E.L., Grobbee D.E., and Van der Schouw Y.T. Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis. Menopause 13 (2006) 265
21. Varas-Lorenzo C., Garcia-Rodriguez L.A., Perez-Gutthann S., and Duque-Oliart A. Hormone replacement therapy and incidence of acute myocardial infarction: a population-based nested case-control study. Circulation 101 (2000) 2572-2578
22. Grodstein F., Stampfer M.J., Manson J.A.E., et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 335 (1996) 453-461
23. Hulley S., Grady D., Bush T., et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Jama 280 (1998) 605-613
24. Manson J.A.E., Hsia J., Johnson K.C., et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 349 (2003) 523-534
25. Rossouw J.E., Prentice R.L., Manson J.A.E., et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. Jama 297 (2007) 1465
26. Salpeter S.R., Walsh J.M.E., Greyber E., and Salpeter E.E. Brief report: coronary heart disease events associated with hormone therapy in younger and older women. J Gen Intern Med 21 (2006) 363-366
27. Grodstein F., Manson J.E., and Stampfer M.J. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Women's Health 15 (2006) 35-44
28. Petitti D.B., Sidney S., and Quesenberry C.P. Oral contraceptive use and myocardial infarction. Contraception 57 (1998) 143-155
29. WHO. Acute myocardial infarction and combined oral contraceptives: results of an international multicentre case-control study. Lancet 349 (1997) 1202-1209
30. Stampfer M.J., Willett W.C., Colditz G.A., Speizer F.E., and Hennekens C.H. A prospective study of past use of oral contraceptive agents and risk of cardiovascular diseases. N Engl J Med 319 (1988) 1313-1317
31. Shufelt C.L., and Bairey Merz C.N. Contraceptive hormone use and cardiovascular disease. J Am Coll Cardiol 53 (2009) 221-231
32. Margolis K.L., Adami H.O., Luo J., Ye W., and Weiderpass E. A prospective study of oral contraceptive use and risk of myocardial infarction among Swedish women. Fertil Steril 88 (2007) 310-316
33. Dunn N., Thorogood M., Faragher B., et al. Oral contraceptives and myocardial infarction: results of the MICA case-control study commentary: oral contraceptives and myocardial infarction: reassuring new findings. BMJ 318 (1999) 1579
34. Stampfer M.J., Willett W.C., Colditz G.A., Speizer F.E., and Hennekens C.H. Past use of oral contraceptives and cardiovascular disease: a meta-analysis in the context of the Nurses' Health Study. Am J Obstet Gynecol 163 (1990) 285-291
35. Prescott E., Hippe M., Schnohr P., Hein H.O., and Vestbo J. Smoking and risk of myocardial infarction in women and men: longitudinal population study. BMJ 316 (1998) 1043-1047
36. Tanis B.C., van den Bosch M.A.A.J., Kemmeren J.M., et al. Oral contraceptives and the risk of myocardial infarction. N Engl J Med 345 (2001) 1787-1793
37. Kannel W.B., and Gordon T. Evaluation of cardiovascular risk in the elderly: the Framingham Study. Bull NY Acad Med 54 (1978) 573-591
38. Hajjar I., and Kotchen T.A. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. Jama 290 (2003) 199-206
39. Rich-Edwards J.W., Manson J.A.E., Hennekens C.H., and Buring J.E. The primary prevention of coronary heart disease in women. N Engl J Med 332 (1995) 1758-1766
40. Huxley R., Barzi F., and Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ 332 (2006) 73-78
41. Hokanson J.E., and Austin M.A. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovas Risk 3 (1996) 213
42. Canoy D., Boekholdt S.M., Wareham N., et al. Body fat distribution and risk of coronary heart disease in men and women in the European prospective investigation into cancer and nutrition in norfolk cohort: a population-based prospective study. Circulation 116 (2007) 2933-2943
43. Vanhecke T.E., Franklin B.A., Miller W.M., deJong A.T., Coleman C.J., and McCullough P.A. Cardiorespiratory fitness and sedentary lifestyle in the morbidly obese. Clin Cardiol 32 (2009) 121-124
44. Blair S.N., Kohl III H.W., Paffenbarger R.S.J., Clark D.G., Cooper K.H., and Gibbons L.W. Physical fitness and all-cause mortality: a prospective study of healthy men and women. Jama 262 (1989) 2395-2401
45. Manson J.E., Greenland P., LaCroix A.Z., et al. Walking compared with vigorous exercise for the prevention of cardiovascular events in women. N Engl J Med 347 (2002) 716-725
46. Tanasescu M., Leitzmann M.F., Rimm E.B., Willett W.C., Stampfer M.J., and Hu F.B. Exercise type and intensity in relation to coronary heart disease in men. Jama 288 (2002) 1994-2000
47. Dahlgren E., Janson P.O., Johansson S., Lapidus L., and Oden A. Polycystic ovary syndrome and risk for myocardial infarction: evaluated from a risk factor model based on a prospective population study of women. Acta Obstet Gynecol Scand 71 (1992) 599-604
48. Birdsall M.A., and Farquhar C.M. Association between polycystic ovaries and extent of coronary artery disease in women having. Ann Intern Med 126 (1997) 32
49. Cibula D., Cifkova R., Fanta M., Poledne R., Zivny J., and Skibova J. Increased risk of non-insulin dependent diabetes mellitus, arterial hypertension and coronary artery disease in perimenopausal women with a history of the polycystic ovary syndrome. Hum Reprod 15 (2000) 785-789
50. Elting M.W., Korsen T.J.M., Bezemer P.D., and Schoemaker J. Prevalence of diabetes mellitus, hypertension and cardiac complaints in a follow-up study of a Dutch PCOS population. Hum Reprod 16 (2001) 556-560
51. Talbott E.O., Zborowski J.V., Rager J.R., Boudreaux M.Y., Edmundowicz D.A., and Guzick D.S. Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome. J Clin Endocrinol Metab 89 (2004) 5454-5461
52. Hannaford P., Ferry S., and Hirsch S. Cardiovascular sequelae of toxaemia of pregnancy. BMJ 77 (1997) 154-158
53. Smith G.C.S., Pell J.P., and Walsh D. Pregnancy complications and maternal risk of ischaemic heart disease: a retrospective cohort study of 129,290 births. Lancet 357 (2001) 2002-2006
54. Kestenbaum B., Seliger S.L., Easterling T.R., et al. Cardiovascular and thromboembolic events following hypertensive pregnancy. Am J Kidney Dis 42 (2003) 982-989
55. Haukkamaa L., Salminen M., Laivuori H., Leinonen H., Hiilesmaa V., and Kaaja R. Risk for subsequent coronary artery disease after preeclampsia. Am J Cardiol 93 (2004) 805-808
56. Funai E.F., Friedlander Y., Paltiel O., et al. Long-term mortality after preeclampsia. Epidemiology 16 (2005) 206
57. Ray J.G., Vermeulen M.J., Schull M.J., and Redelmeier D.A. Cardiovascular health after maternal placental syndromes (CHAMPS): population-based retrospective cohort study. Lancet 366 (2005) 1797-1803
58. Valdes G. Association of remote hypertension in pregnancy with coronary artery disease: a case-control study. Hypertension 53 (2009) 733
59. Van der Schouw Y.T., Van der Graaf Y., Steyerberg E.W., Eijkemans J.C., and Banga J.D. Age at menopause as a risk factor for cardiovascular mortality. Lancet 347 (1996) 714
60. Jacobsen B.K., Nilssen S., Heuch I., and Kvσle G. Does age at natural menopause affect mortality from ischemic heart disease?. J Clin Epidemiol 50 (1997) 475-479
61. Jacobsen B.K., Knutsen S.F., and Fraser G.E. Age at natural menopause and total mortality and mortality from ischemic heart disease the Adventist Health Study. J Clin Epidemiol 52 (1999) 303-307
62. Hu F.B., Grodstein F., Hennekens C.H., et al. Age at natural menopause and risk of cardiovascular disease. Arch Intern Med 159 (1999) 1061-1066
63. Lokkegaard E., Jovanovic Z., Heitmann B.L., Keiding N., Ottesen B., and Pedersen A.T. The association between early menopause and risk of ischaemic heart disease: influence of hormone therapy. Maturitas 53 (2006) 226-233
64. Gordon T., Kannel W.B., Hjortland M.C., and McNamara P.M. Menopause and coronary heart disease. The Framingham Study. Obstet Gynecol Surv 34 (1979) 231
65. Colditz G.A., Willett W.C., Stampfer M.J., Rosner B., Speizer F.E., and Hennekens C.H. Menopause and the risk of coronary heart disease in women. N Engl J Med 316 (1987) 1105-1110
66. Lokkegaard E., Andreasen A.H., Jacobsen R.K., Nielsen L.H., Agger C., and Lidegaard O. Hormone therapy and risk of myocardial infarction: a national register study. Eur Heart J 29 (2008) 2660-2668
67. Lokkegaard E., Pedersen A.T., Heitmann B.L., et al. Relation between hormone replacement therapy and ischaemic heart disease in women: prospective observational study. BMJ 326 (2003) 426
68. Hulley S., Grady D., Bush T., et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Jama 280 (1998) 605-613
69. Grady D., Herrington D., Bittner V., et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). Jama 288 (2002) 49-57
70. Anderson G.L., Limacher M., Assaf A.R., Bassford T., Beresford S.A., and Black H. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. Fam Med (2004)
71. Lewis M.A., Heinemann L.A.J., Spitzer W.O., MacRae K.D., and Bruppacher R. The use of oral contraceptives and the occurrence of acute myocardial infarction in young women: results from the transnational study on oral contraceptives and the health of young women. Contraception 56 (1997) 129-140
72. Sidney S., Siscovick D.S., Petitti D.B., et al. Myocardial infarction and use of low-dose oral contraceptives: a pooled analysis of 2 US studies. Circulation 98 (1998) 1058-1063
73. Rosenberg L., Palmer J.R., Rao R.S., and Shapiro S. Low-dose oral contraceptive use and the risk of myocardial infarction. Arch Intern Med 161 (2001) 1065-1070